Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC assesses pirfenidone for idiopathic pulmonary fibrosis

Published: 10 February 2012

SHTAC is assessing the clinical effectiveness and cost effectiveness of pirfenidone for idiopathic pulmonary fibrosis for the National Institute for Health and Clinical Excellence (NICE) appraisal process.

SHTAC is producing an evidence review for the National Institute for Health and Clinical Excellence (NICE) to inform their single technology appraisal of pirfenidone for idiopathic pulmonary fibrosis. The drug, which is licensed for use in people with mild to moderate idiopathic pulmonary fibrosis, aims to stabilise the disease and slow its progression. Idiopathic pulmonary fibrosis is a progressive, life-threatening disorder of the lungs and currently there are few treatment options available for patients. NICE's guidance on pirfenidone is expected in September 2012.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×